Expression of multidrug resistance 1 and Glutathione-S-Transferase-π protein in nasopharyngeal carcinoma

Chi Long Chen, Tzung Shiahn Sheen, Ia U. Lou, Ai Chun Huang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Radiotherapy is the modality of choice for the treatment of nasopharyngeal carcinoma (NPC). However, systemic chemotherapy has recently been found to play an increasing role in the treatment of advanced or metastatic disease. The status of drug resistance gene expression that has crucial impact on chemotherapy has not been fully addressed for patients with NPC. In this study, we examined the expression of multidrug resistance 1 (MDR-1) and glutathione-Stransferase-π (GST-π) in primary, recurrent, and metastatic NPC using results of immunohistochemical examinations. The results were correlated with the expression of Epstein-Barr virus (EBV) latent protein, latent membrane protein 1 (LMP1), and clinicopathologic features, including stage, histopathologic types, and survival rates. MDR-1 protein expression was detected in 18 (12.6%) of 143 patients with primary NPC, 14 (32.6%) of 43 with recurrent NPC, and O (0%) of 20 with metastatic NPC, whereas 83 (58%) of 143 patients with primary NPC, 30 (69.8%) of 43 with recurrent NPC, and 13 (65%) of 20 with metastatic NPC expressed GST-π. EBV-LMP1 was expressed in 59 (41.3%) of 143 patients with primary NPC, 23 (53.5%) of 43 with recurrent NPC, and 9 (45%) of 20 with metastatic NPC. Simultaneous expression of MDR1 and GST-π was observed in 13 (72.2%) of 18 patients with primary NPC and 12 (85.7%) of 14 with recurrent NPC. The expression of LMP1 was detected in only 6 of the 13 patients with primary NPC and 6 of the 12 with recurrent NPC. We concluded that the expression of GST-π was more frequent in NPC tumor tissues than the expression of MDR-1. The expression of MDR-1 correlated with clinicopathologic features of primary NPC, including the histopathologic types and survival rates, but not with disease stage. The expression of GST-π did not correlate with clinicopathologic features. The expression of MDR-1 and GST-π did not correlate with expression of EBV-LMP1 for patients with NPC.

Original languageEnglish
Pages (from-to)1240-1244
Number of pages5
JournalHuman Pathology
Volume32
Issue number11
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Multiple Drug Resistance
Glutathione Transferase
Proteins
Glutathione
Nasopharyngeal carcinoma
Membrane Proteins
Survival Rate
Drug Therapy
P-Glycoprotein

Keywords

  • Epstein-Barr virus
  • Glutathione-S-transferase-π
  • Latent membrane protein 1
  • Multidrug resistance 1
  • Nasopharyngeal carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Expression of multidrug resistance 1 and Glutathione-S-Transferase-π protein in nasopharyngeal carcinoma. / Chen, Chi Long; Sheen, Tzung Shiahn; Lou, Ia U.; Huang, Ai Chun.

In: Human Pathology, Vol. 32, No. 11, 2001, p. 1240-1244.

Research output: Contribution to journalArticle

Chen, Chi Long ; Sheen, Tzung Shiahn ; Lou, Ia U. ; Huang, Ai Chun. / Expression of multidrug resistance 1 and Glutathione-S-Transferase-π protein in nasopharyngeal carcinoma. In: Human Pathology. 2001 ; Vol. 32, No. 11. pp. 1240-1244.
@article{6491b683815a4e2e83df1515cf03ad67,
title = "Expression of multidrug resistance 1 and Glutathione-S-Transferase-π protein in nasopharyngeal carcinoma",
abstract = "Radiotherapy is the modality of choice for the treatment of nasopharyngeal carcinoma (NPC). However, systemic chemotherapy has recently been found to play an increasing role in the treatment of advanced or metastatic disease. The status of drug resistance gene expression that has crucial impact on chemotherapy has not been fully addressed for patients with NPC. In this study, we examined the expression of multidrug resistance 1 (MDR-1) and glutathione-Stransferase-π (GST-π) in primary, recurrent, and metastatic NPC using results of immunohistochemical examinations. The results were correlated with the expression of Epstein-Barr virus (EBV) latent protein, latent membrane protein 1 (LMP1), and clinicopathologic features, including stage, histopathologic types, and survival rates. MDR-1 protein expression was detected in 18 (12.6{\%}) of 143 patients with primary NPC, 14 (32.6{\%}) of 43 with recurrent NPC, and O (0{\%}) of 20 with metastatic NPC, whereas 83 (58{\%}) of 143 patients with primary NPC, 30 (69.8{\%}) of 43 with recurrent NPC, and 13 (65{\%}) of 20 with metastatic NPC expressed GST-π. EBV-LMP1 was expressed in 59 (41.3{\%}) of 143 patients with primary NPC, 23 (53.5{\%}) of 43 with recurrent NPC, and 9 (45{\%}) of 20 with metastatic NPC. Simultaneous expression of MDR1 and GST-π was observed in 13 (72.2{\%}) of 18 patients with primary NPC and 12 (85.7{\%}) of 14 with recurrent NPC. The expression of LMP1 was detected in only 6 of the 13 patients with primary NPC and 6 of the 12 with recurrent NPC. We concluded that the expression of GST-π was more frequent in NPC tumor tissues than the expression of MDR-1. The expression of MDR-1 correlated with clinicopathologic features of primary NPC, including the histopathologic types and survival rates, but not with disease stage. The expression of GST-π did not correlate with clinicopathologic features. The expression of MDR-1 and GST-π did not correlate with expression of EBV-LMP1 for patients with NPC.",
keywords = "Epstein-Barr virus, Glutathione-S-transferase-π, Latent membrane protein 1, Multidrug resistance 1, Nasopharyngeal carcinoma",
author = "Chen, {Chi Long} and Sheen, {Tzung Shiahn} and Lou, {Ia U.} and Huang, {Ai Chun}",
year = "2001",
doi = "10.1053/hupa.2001.28950",
language = "English",
volume = "32",
pages = "1240--1244",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders",
number = "11",

}

TY - JOUR

T1 - Expression of multidrug resistance 1 and Glutathione-S-Transferase-π protein in nasopharyngeal carcinoma

AU - Chen, Chi Long

AU - Sheen, Tzung Shiahn

AU - Lou, Ia U.

AU - Huang, Ai Chun

PY - 2001

Y1 - 2001

N2 - Radiotherapy is the modality of choice for the treatment of nasopharyngeal carcinoma (NPC). However, systemic chemotherapy has recently been found to play an increasing role in the treatment of advanced or metastatic disease. The status of drug resistance gene expression that has crucial impact on chemotherapy has not been fully addressed for patients with NPC. In this study, we examined the expression of multidrug resistance 1 (MDR-1) and glutathione-Stransferase-π (GST-π) in primary, recurrent, and metastatic NPC using results of immunohistochemical examinations. The results were correlated with the expression of Epstein-Barr virus (EBV) latent protein, latent membrane protein 1 (LMP1), and clinicopathologic features, including stage, histopathologic types, and survival rates. MDR-1 protein expression was detected in 18 (12.6%) of 143 patients with primary NPC, 14 (32.6%) of 43 with recurrent NPC, and O (0%) of 20 with metastatic NPC, whereas 83 (58%) of 143 patients with primary NPC, 30 (69.8%) of 43 with recurrent NPC, and 13 (65%) of 20 with metastatic NPC expressed GST-π. EBV-LMP1 was expressed in 59 (41.3%) of 143 patients with primary NPC, 23 (53.5%) of 43 with recurrent NPC, and 9 (45%) of 20 with metastatic NPC. Simultaneous expression of MDR1 and GST-π was observed in 13 (72.2%) of 18 patients with primary NPC and 12 (85.7%) of 14 with recurrent NPC. The expression of LMP1 was detected in only 6 of the 13 patients with primary NPC and 6 of the 12 with recurrent NPC. We concluded that the expression of GST-π was more frequent in NPC tumor tissues than the expression of MDR-1. The expression of MDR-1 correlated with clinicopathologic features of primary NPC, including the histopathologic types and survival rates, but not with disease stage. The expression of GST-π did not correlate with clinicopathologic features. The expression of MDR-1 and GST-π did not correlate with expression of EBV-LMP1 for patients with NPC.

AB - Radiotherapy is the modality of choice for the treatment of nasopharyngeal carcinoma (NPC). However, systemic chemotherapy has recently been found to play an increasing role in the treatment of advanced or metastatic disease. The status of drug resistance gene expression that has crucial impact on chemotherapy has not been fully addressed for patients with NPC. In this study, we examined the expression of multidrug resistance 1 (MDR-1) and glutathione-Stransferase-π (GST-π) in primary, recurrent, and metastatic NPC using results of immunohistochemical examinations. The results were correlated with the expression of Epstein-Barr virus (EBV) latent protein, latent membrane protein 1 (LMP1), and clinicopathologic features, including stage, histopathologic types, and survival rates. MDR-1 protein expression was detected in 18 (12.6%) of 143 patients with primary NPC, 14 (32.6%) of 43 with recurrent NPC, and O (0%) of 20 with metastatic NPC, whereas 83 (58%) of 143 patients with primary NPC, 30 (69.8%) of 43 with recurrent NPC, and 13 (65%) of 20 with metastatic NPC expressed GST-π. EBV-LMP1 was expressed in 59 (41.3%) of 143 patients with primary NPC, 23 (53.5%) of 43 with recurrent NPC, and 9 (45%) of 20 with metastatic NPC. Simultaneous expression of MDR1 and GST-π was observed in 13 (72.2%) of 18 patients with primary NPC and 12 (85.7%) of 14 with recurrent NPC. The expression of LMP1 was detected in only 6 of the 13 patients with primary NPC and 6 of the 12 with recurrent NPC. We concluded that the expression of GST-π was more frequent in NPC tumor tissues than the expression of MDR-1. The expression of MDR-1 correlated with clinicopathologic features of primary NPC, including the histopathologic types and survival rates, but not with disease stage. The expression of GST-π did not correlate with clinicopathologic features. The expression of MDR-1 and GST-π did not correlate with expression of EBV-LMP1 for patients with NPC.

KW - Epstein-Barr virus

KW - Glutathione-S-transferase-π

KW - Latent membrane protein 1

KW - Multidrug resistance 1

KW - Nasopharyngeal carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0035190727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035190727&partnerID=8YFLogxK

U2 - 10.1053/hupa.2001.28950

DO - 10.1053/hupa.2001.28950

M3 - Article

VL - 32

SP - 1240

EP - 1244

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 11

ER -